7269-14-9

Usage

Uses

Used in Pharmaceutical Applications:
2,4(1H,3H)-Pyrimidinedione, 3-phenyl-6-(phenylamino)is utilized as a pharmaceutical agent for its demonstrated antitumor, antiviral, and antibacterial properties. Its multifaceted biological activities make it a valuable compound in the development of new drugs targeting a range of health conditions.
Used in Research Applications:
In the scientific community, 2,4(1H,3H)-Pyrimidinedione, 3-phenyl-6-(phenylamino)serves as a key research tool. It is employed in studies aimed at understanding the mechanisms of action behind its biological activities, which can lead to the discovery of novel therapeutic strategies and the improvement of existing treatments.
Used in Disease Treatment:
2,4(1H,3H)-Pyrimidinedione, 3-phenyl-6-(phenylamino)is being investigated for its potential use in the treatment of various diseases and disorders. Its broad spectrum of biological activities suggests that it could be a versatile compound in addressing different health challenges, pending further research and clinical trials.

Upstream product

• 62-53-3 aniline 
• 5759-75-1 6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 84459-44-9 3,10-Diphenyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 
• 84459-45-0 8-Chloro-3,10-diphenyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 
• 79157-11-2 3,7,10-Triphenylpyrido<2,3-d:6,5-d'>dipyrimidine-2,4,6,8(1H,3H,7H,10H)-tetraone 
• 1079130-30-5 C₄₄H₅₃N₃O₂ 

Relevant academic research and scientific papers

Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds

Novel deazaflavin-cholestane hybrid compounds, 3′,8′-disubstituted-5′-deazacholest-2,4-dieno[2,3-g]pteridine-2′,4′(3′H,8′H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46).

Autorecycling Oxidation of Alcohols Catalysed by Pyridopyrimidines as an NAD(P)(1+) Model

Two kinds of pyridopyrimidines as new NAD-type redox catalysts, 3,7,10-trisubstituted pyridodipyrimidine-2,4,6,8(1H,3H,7H,10H)-tetraones 6 and 3,8,10-trisubstituted pyridodipyrimidine-2,4,6(3H,7H,10H)-triones 7, have been synthesized by the condensation of 6-(substituted-amino)uracils 9 and 6-(substituted-amino)-2-phenylpyrimidin-4(3H)-ones 11 with appropriate 6-chloro-5-formyluracils 12 or 2,4,6-trichloropyrimidine-5-carbaldehyde 13 in dimethylformamide (DMF) or acetic acid.Compounds 6 and 7 have been found to oxidize a variety of alcohols under neutral conditions (in the absence of base) to yield the corresponding carbonyl compounds, catalytically with a markedly high turnover number.The oxidation yields were promoted remarkably depending upon the presence of lipophilic substituents, particularly due to the presence of longer alkyl groups at the 10-position.These catalysts are so stable that the oxidation reaction proceeds until the substrate is exhausted.